切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™ PE正选试剂盒 II

PE 偶联抗体标记细胞的免疫磁珠正选
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #17684_C

PE 偶联抗体标记细胞的免疫磁珠正选

产品优势

  • 快捷、操作简单          
  • 无需分离柱

产品组分包括

  • EasySep™ PE 正选试剂盒 II（产品号 #17684）
    • EasySep™ PE分选抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™磁珠，1 mL
    • RoboSep™ 偶联一抗专用管（手动操作无需使用），1支
  • RoboSep™ PE正选 试剂盒 II (产品号 #17684RF)
    • EasySep™ PE分选抗体混合物，1 mL
    • EasySep™ Dextran RapidSpheres™磁珠，1 mL
    • RoboSep™ 偶联一抗专用管（手动操作无需使用），1支
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™ 过滤吸头（产品号 #20125）x 2
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. EasySep™ Buffer
    EasySep™ Buffer

    Cell separation buffer

总览
产品说明书及文档
相关材料与文献
相关产品

总览

使用EasySep™ PE正选 试剂盒 II，通过免疫磁珠正选，可从任何单细胞悬液样本中分离高纯度的藻红蛋白(PE)偶联抗体标记的细胞。EasySep™结合了单克隆抗体的特异性和无柱磁性系统的简便性，迄今已广泛应用于发表的研究中超过20年。    

在此EasySep™正选过程中，目的细胞被识别PE的抗体复合物和磁珠结合标记，使用EasySep™进行无柱分选，只需倾倒或吸弃非目的 细胞，目标细胞则保留在管中。磁珠分选获得的PE阳性细胞即可用于下游应用。

该产品可替代EasySep™PE 正选试剂盒 (产品号 #18557) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别PE的抗体复合物和磁珠结合标记，使用EasySep™进行无柱分选，只需倾倒或吸弃非目的 细胞，目标细胞则保留在管中。磁珠分选获得的PE阳性细胞即可用于下游应用。

该产品可替代EasySep™PE 正选试剂盒 (产品号 #18557) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别PE的抗体复合物和磁珠结合标记，使用EasySep™进行无柱分选，只需倾倒或吸弃非目的 细胞，目标细胞则保留在管中。磁珠分选获得的PE阳性细胞即可用于下游应用。

该产品可替代EasySep™PE 正选试剂盒 (产品号 #18557) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

在此EasySep™正选过程中，目的细胞被识别PE的抗体复合物和磁珠结合标记，使用EasySep™进行无柱分选，只需倾倒或吸弃非目的 细胞，目标细胞则保留在管中。磁珠分选获得的PE阳性细胞即可用于下游应用。

该产品可替代EasySep™PE 正选试剂盒 (产品号 #18557) 以进行更快的细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现全自动化免疫磁珠细胞分选。探索更多优化您实验流程的产品，包括培养基、添加剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞，树突状细胞（DCs），粒细胞及其亚群，造血干/祖细胞，巨噬细胞，骨髓基质细胞，间充质干/祖细胞，单核细胞，单个核细胞，髓系细胞，NK 细胞，其它细胞系，血浆，T 细胞
 
种属
非人灵长类，其它细胞系，大鼠
 
样本来源
Bone Marrow，Buffy Coat，Cord Blood，Leukapheresis，其它细胞系，PBMC，外周血，Spleen
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep，RoboSep
 
研究领域
免疫
 

查看更多 显示更少

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ PE Positive Selection Kit II
Catalog #
17684
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ PE Positive Selection Kit II
Catalog #
17684RF
Lot #
All
Language
English

相关材料与文献

技术资料 (6)

EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
1:13
Video
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
1:37
Video
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep...

文献 (5)

FACS and immunomagnetic isolation of early erythroid progenitor cells from mouse fetal liver. T. W. Braun et al. STAR protocols 2022 mar

Abstract

Early erythroid progenitors are transit-amplifying cells with high proliferative capacity committed to undergoing red cell differentiation. CD71/CD24low progenitors are less mature and have greater proliferative capacity than CD71/CD24high. We present protocols for isolation of CD71/CD24low progenitors from mouse fetal liver using both fluorescence-activated cell sorting (FACS) and immunomagnetic enrichment. CD71/CD24low progenitors isolated with both approaches show similar transcriptomes at single-cell resolution and exhibit characteristic proliferative responses to glucocorticoids. For complete details on the use and execution of this protocol, please refer to Li et al. (2019).
View publication
Androgen receptor activity in T cells limits checkpoint blockade efficacy. X. Guan et al. Nature 2022 jun

Abstract

Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-tumour immunity in solid tumours. In patients with advanced prostate cancer, immunotherapy treatments have largely failed1-5. Androgen deprivation therapy is classically administered in these patients to inhibit tumour cell growth, and we postulated that this therapy also affects tumour-associated T cells. Here we demonstrate that androgen receptor (AR) blockade sensitizes tumour-bearing hosts to effective checkpoint blockade by directly enhancing CD8 T cell function. Inhibition of AR activity in CD8 T cells prevented T cell exhaustion and improved responsiveness to PD-1 targeted therapy via increased IFN$\gamma$ expression. AR bound directly to Ifng and eviction of AR with a small molecule significantly increased cytokine production in CD8 T cells. Together, our findings establish that T cell intrinsic AR activity represses IFN$\gamma$ expression and represents a novel mechanism of immunotherapy resistance.
View publication
Myeloid cell-targeted miR-146a mimic inhibits NF-$\kappa$B-driven inflammation and leukemia progression in vivo. Y.-L. Su et al. Blood 2020 jan

Abstract

NF-$\kappa$B is a key regulator of inflammation and cancer progression, with an important role in leukemogenesis. Despite its therapeutic potential, targeting NF-$\kappa$B using pharmacologic inhibitors has proven challenging. Here, we describe a myeloid cell-selective NF-$\kappa$B inhibitor using an miR-146a mimic oligonucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a). Unlike an unconjugated miR146a, C-miR146a was rapidly internalized and delivered to the cytoplasm of target myeloid cells and leukemic cells. C-miR146a reduced expression of classic miR-146a targets (IRAK1 and TRAF6), thereby blocking activation of NF-$\kappa$B in target cells. IV injections of C-miR146a mimic to miR-146a-deficient mice prevented excessive NF-$\kappa$B activation in myeloid cells, and thus alleviated myeloproliferation and mice hypersensitivity to bacterial challenge. Importantly, C-miR146a showed efficacy in dampening severe inflammation in clinically relevant models of chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome. Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent release of IL-1 and IL-6 in a xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-cell antitumor activity. Beyond anti-inflammatory functions, miR-146a is a known tumor suppressor commonly deleted or expressed at reduced levels in human myeloid leukemia. Using The Cancer Genome Atlas acute myeloid leukemia data set, we found an inverse correlation of miR-146a levels with NF-$\kappa$B-related genes and with patient survival. Correspondingly, C-miR146a induced cytotoxic effects in human MDSL, HL-60, and MV4-11 leukemia cells in vitro. The repeated IV administration of C-miR146a inhibited expression of NF-$\kappa$B target genes and thereby thwarted progression of disseminated HL-60 leukemia. Our results show the potential of using myeloid cell-targeted miR-146a mimics for the treatment of inflammatory and myeloproliferative disorders.
View publication
View All Publications

更多信息

更多信息
种属 Non-Human Primate, Other, Rat
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 Bone Marrow, Buffy Coat, Cord Blood, Leukapheresis, Other, PBMC, Peripheral Blood, Spleen
Selection Method Positive
法律声明:

Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. 质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.